Company / Net Income
ADMA Biologics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$146.9M
FY2025
5-year range
-$71.6M / $197.7M
FY2021-FY2025
Trend
-25.7%
vs FY2024
Sector context
#40 of 216
Health Care
What the data says
ADMA Biologics, Inc.'s net income of $147M is higher than 81% of companies in the Health Care sector (FY2025). Net Income has fluctuated over the past 10 years, ranging from -$76M in FY2020 to $198M in FY2024.
Based on SEC 10-K filings.
$147M in FY2025. Top quartile in the Health Care sector.
Improved from -$28M to $147M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 216This company $146.9M Sector average $454.1M
▼
-67.6% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 25.7% year-over-year.
- Ranks #40 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
- Lowest net income in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $146.9M | -25.7% |
| FY2024 | $197.7M | +800.0% |
| FY2023 | -$28.2M | +60.6% |
| FY2022 | -$71.6M | +0.0% |
| FY2021 | -$71.6M | +5.4% |
| FY2020 | -$75.7M | -56.9% |
| FY2019 | -$48.3M | +26.6% |
| FY2018 | -$65.7M | -236.9% |
| FY2017 | -$19.5M | +0.0% |
| FY2016 | -$19.5M | -16.1% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026